The global dystrophic epidermolysis bullosa management market is projected to achieve a value of USD 452.37 million in 2023, with an expected compound annual growth rate (CAGR) of 5.7% from 2023 to 2033. This growth is primarily fueled by the high prevalence of skin diseases and the increasing incidence of dystrophic epidermolysis bullosa (DEB), a rare genetic condition characterized by fragile skin that blisters easily.
As awareness of DEB rises and research into innovative management strategies progresses, the market is anticipated to expand significantly. The rising demand for effective treatment options and improved quality of life for patients are key factors contributing to the growth of the dystrophic epidermolysis bullosa management market.
With a focus on developing advanced therapies and supportive care, stakeholders in the healthcare sector are working to address the challenges posed by this debilitating condition. The continued commitment to research and development in this area is expected to yield significant advancements, ultimately benefiting patients affected by dystrophic epidermolysis bullosa.
Children with RDEB may develop malignant melanoma and adults with EB simplex are at a very high risk of basal cell carcinoma. Patient-centered approach to treating EB is expected to further grow in the market. In order for a plan to be tailored to each individual patient, healthcare professionals use preventative measures, nutritional support, and wound care treatments. In addition to monitoring and updating the patient’s treatment plan, assessment of skin lesions and general health tools are expected to grow.
The outcome of antibiotic treatment depends on the infectious status of the wound and the result of an antibiogram. As a result of the recommended strategies, dermatologists will be able to develop individualized care plans for patients with EB. The proposed monitoring instruments can be used to continuously update the treatment plan for the patient, as well as the national recommendations for the management of EB, based on the data provided by the proposed monitoring tools. Further, it may be possible to offer whole exome sequences or targeted panels as part of the next-generation sequencing process. Low cost and rapid turnaround time will be provided by targeted panels that include the testing of commonly found genes with 94.3% efficiency and 75-98 sensitivity.
Competitive Landscape
Researchers and developers are developing new products and devices for diagnosis and treatment in the global dystrophic epidermolysis bullosa management market. These new developments are expected to lead to a number of new treatments being launched within the next few years. Companies have a competitive advantage over their competitors when they obtain approval for new products in a timely manner.
- In January 2023, Krystal Biotech, Inc. announced that it had received approval from the USA Food and Drug Administration (FDA) informed the Company that the PDUFA date has been revised to May 19, 2023, as a result of manufacturing information the Agency received from the Company on December 20, 2022, in response to a regulatory update for B-VEC to treat patients with Dystrophic epidermolysis bullosa. Labeling discussions have also been pushed back until April 20, 2023. A replacement hardware unit was included in the manufacturing information submitted by the Company, as well as comparable data supporting its use.
- Amryt, an international biopharmaceutical company dedicated to developing, commercializing, and acquiring proprietary treatments for rare diseases, has announced that Phase 3 of the APH-19 trial showed positive results with lomitapide in children with HoFH (homozygous familial hypercholesterolemia).
Key Companies Profiled
- Castle Creek Biosciences
- Amryth Pharma
- Krystal Biotech
- Abeona Therapeutics
- BridgeBio
- Phoenix Tissue Repair
- Wings Therapeutics
- InMed Pharmaceuticals, Inc.
- Regenerx Biopharmaceuticals Inc.
- Holostem Terapie Avanzate S.r.l.
Key Segments Profiled in the Dystrophic Epidermolysis Bullosa Management Industry Survey?
By Disease Type:
- Dominant Dystrophic Epidermolysis Bullosa (DDEB)
- Recessive Dystrophic Epidermolysis Bullosa (RDEB)
By Drug Class:
- Antibiotics
- Corticosteroids
- Opioid Analgesics
- Anticonvulsant
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
